APO Research
Talk to an analyst

APO RESEARCH · REPORT

Alpha-1 Antitrypsin Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Alpha-1 Antitrypsin Drugs Market Outlook and Growth Opportunities 2026

20 December 2025196 pages

Choose your research edition.

Industry ResearchAlpha-1 Antitrypsin Drugs Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Alpha-1 Antitrypsin Drugs Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Alpha-1 Antitrypsin Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Alpha-1 Antitrypsin Drugs Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Alpha-1 Antitrypsin Drugs Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Alpha-1 Antitrypsin Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Alpha-1 Antitrypsin Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Alpha-1 Antitrypsin Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Alpha-1 Antitrypsin Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Alpha-1 Antitrypsin Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Alpha-1 Antitrypsin Drugs market include Baxter, Kamada, Grifols, CSL Behring, Baxalta, Arrowhead Research Corporation, Applied Genetic Technologies Corp, Alnylam Pharmaceuticals and Abeona Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Alpha-1 Antitrypsin Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Alpha-1 Antitrypsin Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Alpha-1 Antitrypsin Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Alpha-1 Antitrypsin Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Alpha-1 Antitrypsin Drugs Segment by Company

Baxter

Kamada

Grifols

CSL Behring

Baxalta

Arrowhead Research Corporation

Applied Genetic Technologies Corp

Alnylam Pharmaceuticals

Abeona Therapeutics

Alpha-1 Antitrypsin Drugs Segment by Type

Parenteral

Inhalation

Alpha-1 Antitrypsin Drugs Segment by Application

Drugstore

Hospital

Others

Alpha-1 Antitrypsin Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Alpha-1 Antitrypsin Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Alpha-1 Antitrypsin Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Alpha-1 Antitrypsin Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Alpha-1 Antitrypsin Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Alpha-1 Antitrypsin Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Alpha-1 Antitrypsin Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Alpha-1 Antitrypsin Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Alpha-1 Antitrypsin Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Alpha-1 Antitrypsin Drugs industry.

Chapter 3: Detailed analysis of Alpha-1 Antitrypsin Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Alpha-1 Antitrypsin Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Alpha-1 Antitrypsin Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Alpha-1 Antitrypsin Drugs Industry Trends Table 2. Alpha-1 Antitrypsin Drugs Industry Drivers Table 3. Alpha-1 Antitrypsin Drugs Industry Opportunities and Challenges Table 4. Alpha-1 Antitrypsin Drugs Industry Restraints Table 5. Global Alpha-1 Antitrypsin Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Alpha-1 Antitrypsin Drugs Revenue Share by Company (2021-2026) Table 7. Global Alpha-1 Antitrypsin Drugs Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Alpha-1 Antitrypsin Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Alpha-1 Antitrypsin Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Alpha-1 Antitrypsin Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Alpha-1 Antitrypsin Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Alpha-1 Antitrypsin Drugs Company, Product Type & Application Table 13. Global Alpha-1 Antitrypsin Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Alpha-1 Antitrypsin Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Parenteral Table 18. Significant Companies of Inhalation Table 19. Global Alpha-1 Antitrypsin Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 20. Global Alpha-1 Antitrypsin Drugs Sales Volume by Type (2021-2026) & (W Units) Table 21. Global Alpha-1 Antitrypsin Drugs Sales Volume by Type (2027-2032) & (W Units) Table 22. Global Alpha-1 Antitrypsin Drugs Sales Volume Share by Type (2021-2026) Table 23. Global Alpha-1 Antitrypsin Drugs Sales Volume Share by Type (2027-2032) Table 24. Global Alpha-1 Antitrypsin Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Alpha-1 Antitrypsin Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Alpha-1 Antitrypsin Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Alpha-1 Antitrypsin Drugs Sales Value Share by Type (2021-2026) Table 28. Global Alpha-1 Antitrypsin Drugs Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Drugstore Table 30. Significant Companies of Hospital Table 31. Significant Companies of Others Table 32. Global Alpha-1 Antitrypsin Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 33. Global Alpha-1 Antitrypsin Drugs Sales Volume by Application (2021-2026) & (W Units) Table 34. Global Alpha-1 Antitrypsin Drugs Sales Volume by Application (2027-2032) & (W Units) Table 35. Global Alpha-1 Antitrypsin Drugs Sales Volume Share by Application (2021-2026) Table 36. Global Alpha-1 Antitrypsin Drugs Sales Volume Share by Application (2027-2032) Table 37. Global Alpha-1 Antitrypsin Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Alpha-1 Antitrypsin Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Alpha-1 Antitrypsin Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Alpha-1 Antitrypsin Drugs Sales Value Share by Application (2021-2026) Table 41. Global Alpha-1 Antitrypsin Drugs Sales Value Share by Application (2027-2032) Table 42. Global Alpha-1 Antitrypsin Drugs Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 43. Global Alpha-1 Antitrypsin Drugs Sales by Region (2021-2026) & (W Units) Table 44. Global Alpha-1 Antitrypsin Drugs Sales Market Share by Region (2021-2026) Table 45. Global Alpha-1 Antitrypsin Drugs Sales by Region (2027-2032) & (W Units) Table 46. Global Alpha-1 Antitrypsin Drugs Sales Market Share by Region (2027-2032) Table 47. Global Alpha-1 Antitrypsin Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Alpha-1 Antitrypsin Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Alpha-1 Antitrypsin Drugs Sales Value Share by Region (2021-2026) Table 50. Global Alpha-1 Antitrypsin Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Alpha-1 Antitrypsin Drugs Sales Value Share by Region (2027-2032) Table 52. Global Alpha-1 Antitrypsin Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Alpha-1 Antitrypsin Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Alpha-1 Antitrypsin Drugs Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 55. Global Alpha-1 Antitrypsin Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Alpha-1 Antitrypsin Drugs Sales by Country (2021-2026) & (W Units) Table 57. Global Alpha-1 Antitrypsin Drugs Sales Market Share by Country (2021-2026) Table 58. Global Alpha-1 Antitrypsin Drugs Sales by Country (2027-2032) & (W Units) Table 59. Global Alpha-1 Antitrypsin Drugs Sales Market Share by Country (2027-2032) Table 60. Global Alpha-1 Antitrypsin Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Alpha-1 Antitrypsin Drugs Sales Value Market Share by Country (2021-2026) Table 62. Global Alpha-1 Antitrypsin Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Alpha-1 Antitrypsin Drugs Sales Value Market Share by Country (2027-2032) Table 64. Baxter Company Information Table 65. Baxter Business Overview Table 66. Baxter Alpha-1 Antitrypsin Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Baxter Alpha-1 Antitrypsin Drugs Product Portfolio Table 68. Baxter Recent Development Table 69. Kamada Company Information Table 70. Kamada Business Overview Table 71. Kamada Alpha-1 Antitrypsin Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Kamada Alpha-1 Antitrypsin Drugs Product Portfolio Table 73. Kamada Recent Development Table 74. Grifols Company Information Table 75. Grifols Business Overview Table 76. Grifols Alpha-1 Antitrypsin Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Grifols Alpha-1 Antitrypsin Drugs Product Portfolio Table 78. Grifols Recent Development Table 79. CSL Behring Company Information Table 80. CSL Behring Business Overview Table 81. CSL Behring Alpha-1 Antitrypsin Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. CSL Behring Alpha-1 Antitrypsin Drugs Product Portfolio Table 83. CSL Behring Recent Development Table 84. Baxalta Company Information Table 85. Baxalta Business Overview Table 86. Baxalta Alpha-1 Antitrypsin Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Baxalta Alpha-1 Antitrypsin Drugs Product Portfolio Table 88. Baxalta Recent Development Table 89. Arrowhead Research Corporation Company Information Table 90. Arrowhead Research Corporation Business Overview Table 91. Arrowhead Research Corporation Alpha-1 Antitrypsin Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Arrowhead Research Corporation Alpha-1 Antitrypsin Drugs Product Portfolio Table 93. Arrowhead Research Corporation Recent Development Table 94. Applied Genetic Technologies Corp Company Information Table 95. Applied Genetic Technologies Corp Business Overview Table 96. Applied Genetic Technologies Corp Alpha-1 Antitrypsin Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Applied Genetic Technologies Corp Alpha-1 Antitrypsin Drugs Product Portfolio Table 98. Applied Genetic Technologies Corp Recent Development Table 99. Alnylam Pharmaceuticals Company Information Table 100. Alnylam Pharmaceuticals Business Overview Table 101. Alnylam Pharmaceuticals Alpha-1 Antitrypsin Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Alnylam Pharmaceuticals Alpha-1 Antitrypsin Drugs Product Portfolio Table 103. Alnylam Pharmaceuticals Recent Development Table 104. Abeona Therapeutics Company Information Table 105. Abeona Therapeutics Business Overview Table 106. Abeona Therapeutics Alpha-1 Antitrypsin Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Abeona Therapeutics Alpha-1 Antitrypsin Drugs Product Portfolio Table 108. Abeona Therapeutics Recent Development Table 109. Key Raw Materials Table 110. Raw Materials Key Suppliers Table 111. Alpha-1 Antitrypsin Drugs Distributors List Table 112. Alpha-1 Antitrypsin Drugs Customers List Table 113. Research Programs/Design for This Report Table 114. Authors List of This Report Table 115. Secondary Sources Table 116. Primary Sources List of Figures Figure 1. Alpha-1 Antitrypsin Drugs Product Image Figure 2. Global Alpha-1 Antitrypsin Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Alpha-1 Antitrypsin Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Alpha-1 Antitrypsin Drugs Sales (2021-2032) & (W Units) Figure 5. Global Alpha-1 Antitrypsin Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Alpha-1 Antitrypsin Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Parenteral Image Figure 10. Inhalation Image Figure 11. Global Alpha-1 Antitrypsin Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 12. Global Alpha-1 Antitrypsin Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Alpha-1 Antitrypsin Drugs Sales Volume Share by Type (2021-2032) Figure 14. Global Alpha-1 Antitrypsin Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Alpha-1 Antitrypsin Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Alpha-1 Antitrypsin Drugs Sales Value Share by Type (2021-2032) Figure 17. Drugstore Image Figure 18. Hospital Image Figure 19. Others Image Figure 20. Global Alpha-1 Antitrypsin Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 21. Global Alpha-1 Antitrypsin Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Alpha-1 Antitrypsin Drugs Sales Volume Share by Application (2021-2032) Figure 23. Global Alpha-1 Antitrypsin Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Alpha-1 Antitrypsin Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Alpha-1 Antitrypsin Drugs Sales Value Share by Application (2021-2032) Figure 26. Global Alpha-1 Antitrypsin Drugs Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 27. Global Alpha-1 Antitrypsin Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Alpha-1 Antitrypsin Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Alpha-1 Antitrypsin Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Alpha-1 Antitrypsin Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. North America Alpha-1 Antitrypsin Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Alpha-1 Antitrypsin Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Alpha-1 Antitrypsin Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Alpha-1 Antitrypsin Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Alpha-1 Antitrypsin Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Alpha-1 Antitrypsin Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. South America Alpha-1 Antitrypsin Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Alpha-1 Antitrypsin Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Alpha-1 Antitrypsin Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Alpha-1 Antitrypsin Drugs Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Alpha-1 Antitrypsin Drugs Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Parenteral
  • Inhalation
Applications
  • Drugstore
  • Hospital
  • Others
Companies covered
  • Baxter
  • Kamada
  • Grifols
  • CSL Behring
  • Baxalta
  • Arrowhead Research Corporation
  • Applied Genetic Technologies Corp
  • Alnylam Pharmaceuticals
  • Abeona Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Alpha-1 Antitrypsin Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Alpha-1 Antitrypsin Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Alpha-1 Antitrypsin Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Alpha-1 Antitrypsin Drugs Market Dynamics
  1. 2.1 Alpha-1 Antitrypsin Drugs Industry Trends
  2. 2.2 Alpha-1 Antitrypsin Drugs Industry Drivers
  3. 2.3 Alpha-1 Antitrypsin Drugs Industry Opportunities and Challenges
  4. 2.4 Alpha-1 Antitrypsin Drugs Industry Restraints
3 Alpha-1 Antitrypsin Drugs Market by Company
  1. 3.1 Global Alpha-1 Antitrypsin Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Alpha-1 Antitrypsin Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Alpha-1 Antitrypsin Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Alpha-1 Antitrypsin Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Alpha-1 Antitrypsin Drugs Company Ranking (2024-2026)
  6. 3.6 Global Alpha-1 Antitrypsin Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Alpha-1 Antitrypsin Drugs Company Product Type and Application
  8. 3.8 Global Alpha-1 Antitrypsin Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Alpha-1 Antitrypsin Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Alpha-1 Antitrypsin Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Alpha-1 Antitrypsin Drugs Market by Type
  1. 4.1 Alpha-1 Antitrypsin Drugs Type Introduction
  2. 4.1.1 Parenteral
  3. 4.1.2 Inhalation
  4. 4.2 Global Alpha-1 Antitrypsin Drugs Sales Volume by Type
  5. 4.2.1 Global Alpha-1 Antitrypsin Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Alpha-1 Antitrypsin Drugs Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Alpha-1 Antitrypsin Drugs Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Alpha-1 Antitrypsin Drugs Sales Value by Type
  9. 4.3.1 Global Alpha-1 Antitrypsin Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Alpha-1 Antitrypsin Drugs Sales Value by Type (2021-2032)
  11. 4.3.3 Global Alpha-1 Antitrypsin Drugs Sales Value Share by Type (2021-2032)
5 Alpha-1 Antitrypsin Drugs Market by Application
  1. 5.1 Alpha-1 Antitrypsin Drugs Application Introduction
  2. 5.1.1 Drugstore
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Alpha-1 Antitrypsin Drugs Sales Volume by Application
  6. 5.2.1 Global Alpha-1 Antitrypsin Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Alpha-1 Antitrypsin Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Alpha-1 Antitrypsin Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Alpha-1 Antitrypsin Drugs Sales Value by Application
  10. 5.3.1 Global Alpha-1 Antitrypsin Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Alpha-1 Antitrypsin Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Alpha-1 Antitrypsin Drugs Sales Value Share by Application (2021-2032)
6 Alpha-1 Antitrypsin Drugs Regional Sales and Value Analysis
  1. 6.1 Global Alpha-1 Antitrypsin Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Alpha-1 Antitrypsin Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Alpha-1 Antitrypsin Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Alpha-1 Antitrypsin Drugs Sales by Region (2027-2032)
  5. 6.3 Global Alpha-1 Antitrypsin Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Alpha-1 Antitrypsin Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Alpha-1 Antitrypsin Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Alpha-1 Antitrypsin Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Alpha-1 Antitrypsin Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Alpha-1 Antitrypsin Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Alpha-1 Antitrypsin Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Alpha-1 Antitrypsin Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Alpha-1 Antitrypsin Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Alpha-1 Antitrypsin Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Alpha-1 Antitrypsin Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Alpha-1 Antitrypsin Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Alpha-1 Antitrypsin Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Alpha-1 Antitrypsin Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Alpha-1 Antitrypsin Drugs Sales Value Share by Country, 2025 VS 2032
7 Alpha-1 Antitrypsin Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Alpha-1 Antitrypsin Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Alpha-1 Antitrypsin Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Alpha-1 Antitrypsin Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Alpha-1 Antitrypsin Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Alpha-1 Antitrypsin Drugs Sales by Country (2027-2032)
  6. 7.4 Global Alpha-1 Antitrypsin Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Alpha-1 Antitrypsin Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Alpha-1 Antitrypsin Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Alpha-1 Antitrypsin Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Alpha-1 Antitrypsin Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Alpha-1 Antitrypsin Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Baxter
  2. 8.1.1 Baxter Company Information
  3. 8.1.2 Baxter Business Overview
  4. 8.1.3 Baxter Alpha-1 Antitrypsin Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Baxter Alpha-1 Antitrypsin Drugs Product Portfolio
  6. 8.1.5 Baxter Recent Developments
  7. 8.2 Kamada
  8. 8.2.1 Kamada Company Information
  9. 8.2.2 Kamada Business Overview
  10. 8.2.3 Kamada Alpha-1 Antitrypsin Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Kamada Alpha-1 Antitrypsin Drugs Product Portfolio
  12. 8.2.5 Kamada Recent Developments
  13. 8.3 Grifols
  14. 8.3.1 Grifols Company Information
  15. 8.3.2 Grifols Business Overview
  16. 8.3.3 Grifols Alpha-1 Antitrypsin Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Grifols Alpha-1 Antitrypsin Drugs Product Portfolio
  18. 8.3.5 Grifols Recent Developments
  19. 8.4 CSL Behring
  20. 8.4.1 CSL Behring Company Information
  21. 8.4.2 CSL Behring Business Overview
  22. 8.4.3 CSL Behring Alpha-1 Antitrypsin Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 CSL Behring Alpha-1 Antitrypsin Drugs Product Portfolio
  24. 8.4.5 CSL Behring Recent Developments
  25. 8.5 Baxalta
  26. 8.5.1 Baxalta Company Information
  27. 8.5.2 Baxalta Business Overview
  28. 8.5.3 Baxalta Alpha-1 Antitrypsin Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Baxalta Alpha-1 Antitrypsin Drugs Product Portfolio
  30. 8.5.5 Baxalta Recent Developments
  31. 8.6 Arrowhead Research Corporation
  32. 8.6.1 Arrowhead Research Corporation Company Information
  33. 8.6.2 Arrowhead Research Corporation Business Overview
  34. 8.6.3 Arrowhead Research Corporation Alpha-1 Antitrypsin Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Arrowhead Research Corporation Alpha-1 Antitrypsin Drugs Product Portfolio
  36. 8.6.5 Arrowhead Research Corporation Recent Developments
  37. 8.7 Applied Genetic Technologies Corp
  38. 8.7.1 Applied Genetic Technologies Corp Company Information
  39. 8.7.2 Applied Genetic Technologies Corp Business Overview
  40. 8.7.3 Applied Genetic Technologies Corp Alpha-1 Antitrypsin Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Applied Genetic Technologies Corp Alpha-1 Antitrypsin Drugs Product Portfolio
  42. 8.7.5 Applied Genetic Technologies Corp Recent Developments
  43. 8.8 Alnylam Pharmaceuticals
  44. 8.8.1 Alnylam Pharmaceuticals Company Information
  45. 8.8.2 Alnylam Pharmaceuticals Business Overview
  46. 8.8.3 Alnylam Pharmaceuticals Alpha-1 Antitrypsin Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Alnylam Pharmaceuticals Alpha-1 Antitrypsin Drugs Product Portfolio
  48. 8.8.5 Alnylam Pharmaceuticals Recent Developments
  49. 8.9 Abeona Therapeutics
  50. 8.9.1 Abeona Therapeutics Company Information
  51. 8.9.2 Abeona Therapeutics Business Overview
  52. 8.9.3 Abeona Therapeutics Alpha-1 Antitrypsin Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Abeona Therapeutics Alpha-1 Antitrypsin Drugs Product Portfolio
  54. 8.9.5 Abeona Therapeutics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Alpha-1 Antitrypsin Drugs Value Chain Analysis
  2. 9.1.1 Alpha-1 Antitrypsin Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Alpha-1 Antitrypsin Drugs Sales Mode & Process
  6. 9.2 Alpha-1 Antitrypsin Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Alpha-1 Antitrypsin Drugs Distributors
  9. 9.2.3 Alpha-1 Antitrypsin Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst